ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

IOVA Iovance Biotherapeutics Inc

12.88
0.00 (0.00%)
Pre Market
Last Updated: 12:06:19
Delayed by 15 minutes
Share Name Share Symbol Market Type
Iovance Biotherapeutics Inc NASDAQ:IOVA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 12.88 12.88 12.99 6 12:06:19

Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

12/03/2015 10:02am

Edgar (US Regulatory)


 

Prospectus Supplement No. 1

(To Prospectus Dated September 29, 2014)

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-192649

 

LION BIOTECHNOLOGIES, INC.

 

Common Stock

 

This Prospectus Supplement supplements, and should be read in conjunction with, our Prospectus dated September 29, 2014 (the “Prospectus”). This Prospectus Supplement must be delivered with the Prospectus.

 

The information in the Prospectus in the section titled “Selling Stockholders” is amended by this Prospectus Supplement to reflect the transfer by the Estate of Herbert Hillsberg to Mr. Hillsberg’s surviving wife, Madeline Hillsberg, of 50,000 shares of our common stock.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this Prospectus Supplement. Any representation to the contrary is a criminal offense.

 

The date of this Prospectus Supplement is March 11, 2015.

 

 
 

 

SELLING STOCKHOLDERS

 

SUPPLEMENTAL INFORMATION

 

The table beginning on page 57 of the Prospectus in the section titled “Selling Stockholders” is amended as follows.

 

The table is hereby revised to reflect the transfer of 50,000 shares of our common stock from the Estate of Herbert Hillsberg to Madeline Hillsberg, who is Mr. Hillsberg’s surviving wife. Madeline Hillsberg shall henceforth be treated as a selling stockholder for purposes of the Prospectus. The beneficial ownership information for the selling stockholder listed below is as of March 11, 2015.

 

    Beneficial Ownership
Before Offering
      Beneficial Ownership
After Offering
Selling Stockholder   Number of Shares   Percent   Number of Shares Being Offered   Number of Shares   Percent
                     
Madeline Hillsberg   50,000   Under 1.0%   50,000   0   -

 

 
 

 

1 Year Iovance Biotherapeutics Chart

1 Year Iovance Biotherapeutics Chart

1 Month Iovance Biotherapeutics Chart

1 Month Iovance Biotherapeutics Chart

Your Recent History

Delayed Upgrade Clock